Novo Nordisk


Zuellig Pharma
Concise Prescribing Info
Adjunct to reduced-calorie diet & increased physical activity for chronic wt management in adult patients w/ initial BMI of ≥30 kg/m2 or ≥27 kg/m2 to <30 kg/m2 in the presence of at least 1 wt-related comorbidity eg, dysglycaemia (pre-diabetes or type 2 DM), HTN, dyslipidaemia or obstructive sleep apnoea. Adjunct to a healthy nutrition & increased physical activity for wt management in adolescent ≥12 yr w/ obesity (BMI ≥30 kg/m2) or body wt ≥60 kg.
Dosage/Direction for Use
Adult & adolescent ≥12-18 yr Initially 0.6 mg once daily, should be increased to 3 mg once daily in increments of 0.6 mg w/ at least 1 wk interval. Maintenance: 3 mg daily. Max dose: Not to exceed 3 mg.
May be taken with or without food.
Special Precautions
Not to be inj IV or IM. Not to be used as insulin substitute. Discontinue use if pancreatitis is suspected & if wt loss <5% after 12 wk use. Not recommended in patients w/ CHF NYHA class IV; inflammatory bowel disease, diabetic gastroparesis; patients treated w/ other wt management products; obesity secondary to endocrinological or eating disorders or treatment w/ medicinal products causing wt gain. Cholelithiasis, cholecystitis; preexisting thyroid disease; dehydration. Increased risk of hypoglycaemia w/ sulfonylurea. Monitor heart rate at regular intervals. Avoid fluid depletion. Not to be used in combination w/ another GLP-1 receptor agonist. May affect ability to drive & use machines. Mild or moderate hepatic impairment. Not recommended in severe hepatic & renal impairment (CrCl <30 mL/min) including ESRD. Not to be used during pregnancy & lactation. Childn <12 yr. Not recommended in elderly ≥75 yr.
Adverse Reactions
Headache; nausea, vomiting, diarrhoea, constipation. Hypoglycaemia; insomnia; dizziness, dysgeusia; dry mouth, dyspepsia, gastritis, GERD, upper abdominal pain, flatulence, eructation, abdominal distension; cholelithiasis; inj site reactions, asthenia, fatigue; increased lipase & amylase.
Drug Interactions
Decreased Cmax & delayed Tmax of paracetamol & atorvastatin. Increased Cmax of griseofulvin. Reduced AUC & decreased Cmax of digoxin & lisinopril. Lowered Cmax of ethinylestradiol, levonorgestrel. Monitor INR w/ warfarin or other coumarin derivatives.
MIMS Class
Anti-Obesity Agents / Antidiabetic Agents
ATC Classification
A10BJ02 - liraglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Saxenda soln for inj (pre-filled pen) 6 mg/mL
3 mL x 3 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in